Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Research ArticleResearch Article

Oxaliplatin, Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients

Bing Han, Ruihua Xu, Yanxia Shi, Huiyan Luo, Xiaojuan Xiang, Yuhong Li, Li Zhang, Tongyu Lin and Youjian He
Chinese Journal of Clinical Oncology December 2007, 4 (6) 397-400; DOI: https://doi.org/10.1007/s11805-007-0397-9
Bing Han
Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou 510060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruihua Xu
Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou 510060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ruihxu{at}163.com
Yanxia Shi
Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou 510060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huiyan Luo
Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou 510060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaojuan Xiang
Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou 510060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuhong Li
Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou 510060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Zhang
Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou 510060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tongyu Lin
Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou 510060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youjian He
Department of Medical Oncology, Sun Yatsen University Cancer Center, Guangzhou 510060, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Over survival curve for 97 patients.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Over survival curve for 97 patients.

  • TTP survival curve for 97 patients.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    TTP survival curve for 97 patients.

  • Over survival curves for patients with or without radical resection.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Over survival curves for patients with or without radical resection.

  • TTP survival curves for patients with or without radical resection.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    TTP survival curves for patients with or without radical resection.

Tables

  • Figures
    • View popup
    Table 1.

    Clinical characteristics.

    ParameterCases%
    Total105
    Gender
        Male7066.7
        Female3533.3
    Age (years)
        Median (range)53 (21~74)
    Primary site
        Colon5350.5
        Rectum5249.5
    Numbers of evaluatable sites
          13937.1
          276.7
         >25956.2
    Metastatic or recurrent sites
        Liver metastasis4340.9
        Lung metastasis2927.6
        Local recurrence2120.0
        Others4240.0
    • View popup
    Table 2.

    Objective response to treatment.

    Cases%
    Complete response (CR)99.3
    Partial response (PR)2525.8
    Stable disease (SD)3233.0
    Progressive disease (PD)3132.0
    Total97
    • View popup
    Table 3.

    Maximum toxicity per patient (%).

    Grade I/IIGrade III/IV
    Cases%Cases%
    Nausea6971.1
    Vomiting3940.244.1
    Diarrhea3030.977.2
    Neurologic toxicity2626.855.1
    Neutropenia3637.11212.3
    Thrombocytopenia3030.911.0
    Anemia3949.31111.3
PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 4 (6)
Chinese Journal of Clinical Oncology
Vol. 4, Issue 6
December 2007
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Oxaliplatin, Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Oxaliplatin, Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients
Bing Han, Ruihua Xu, Yanxia Shi, Huiyan Luo, Xiaojuan Xiang, Yuhong Li, Li Zhang, Tongyu Lin, Youjian He
Chinese Journal of Clinical Oncology Dec 2007, 4 (6) 397-400; DOI: 10.1007/s11805-007-0397-9

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Oxaliplatin, Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients
Bing Han, Ruihua Xu, Yanxia Shi, Huiyan Luo, Xiaojuan Xiang, Yuhong Li, Li Zhang, Tongyu Lin, Youjian He
Chinese Journal of Clinical Oncology Dec 2007, 4 (6) 397-400; DOI: 10.1007/s11805-007-0397-9
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Radiotherapy in Non-Functioning Pituitary Macroadenoma: Mansoura Experience
  • Expression of the B-Cell Lymphoma/Leukemia 11A Gene in Malignant Hematological Cell Lines through Quantitative Reverse Transcription Polymerase Chain Reaction
  • Monoclonal Antibodies in Cancer Therapy
Show more Research Article

Similar Articles

Keywords

  • oxaliplatin
  • chemotherapy
  • fluorouracil
  • leucovorin
  • colorectal cancer

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire